SCHEMBL6988202

SCHEMBL6988202

COc1ccc2c(c1)S(=O)(=O)NC(C(C)=O)C2=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 6/20 0.42
CA12 O43570 5/20 0.42
CA2 P00918 4/20 0.42
CA1 P00915 5/20 0.42
CA7 P43166 3/20 0.42
CA4 P22748 2/20 0.42
SLC40A1 Q9NP59 1/20 0.39
ELANE P08246 1/20 0.38
PTGES O14684 1/20 0.37
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPT P10636 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6994911 0.89 L3MBTL1 (0.41) CA9CA12CA2CA1CA7
SCHEMBL6988782 0.81 KDM4E (0.44) CA9CA12CA2CA1CA7
SCHEMBL5186168 0.73 CA12 (0.63) CA9CA12CA2CA1CA7
SCHEMBL6992810 0.72 CHEK1 (0.49) CA9CA12CA2CA1CA7
SCHEMBL6997184 0.70 KCNA5 (0.37) CA9CA12CA2CA1CA7
SCHEMBL31536352 0.69 MAPKAPK2 (0.40) CA9CA12CA2CA1CA7
SCHEMBL11235866 0.68 KMT2A (0.44) CA9CA12CA2CA1CA7
SCHEMBL5185504 0.67 GRIA2 (0.47) CA9CA12CA2CA1CA7
SCHEMBL12275362 0.67 RYR2 (0.40) CA9CA12CA2CA1CA7
SCHEMBL26767766 0.66 CA12 (0.56) CA9CA12CA2CA1CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6664251-B2 Serotonin receptor antagonist; treating cardiovascular disorder DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2003-12-16 US disclosed
US-20030078256-A1 Benzothiazine derivative SUNTORY LIMITED (JP) 2003-04-24 US disclosed
EP-0749967-B1 Substituted benzothiazine derivative SUNTORY LTD (JP) 2003-01-22 EP disclosed
US-6316442-B1 TREATMENT OF HEART DISEASE AND CEREBROVASCULAR DISTURBANCES SUNTORY LIMITED (JP) 2001-11-13 US disclosed
US-6001827-A Benzothiazine derivative SUNTORY LIMITED (JP) 1999-12-14 US disclosed
US-5874429-A ANTIISCHEMIC AGENTS; CEREBROVASCULAR DISORDERS; CIRCULATORY IDSORDERS SUNTORY LIMITED (JP) 1999-02-23 US disclosed
EP-0749967-A1 Substituted benzothiazine derivative SUNTORY LIMITED (JP) 1996-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078256-A1 Benzothiazine derivative TPH2, ADRB2, TPH1 CA9 4680/4885CA12 4559/4885CA2 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.